Long-term lorcainide therapy in patients with ventricular tachycardia.
Publication/Presentation Date
1-1-1985
Abstract
One hundred patients inducible at electrophysiologic studies underwent serial drug testing with procainamide, lidocaine, and lorcainide to determine comparative efficacy. Acute intravenous administration was followed by repeat programmed electrical stimulation (PES) studies on separate days for each antiarrhythmic drug. Lorcainide prevented ventricular tachycardia (VT) induction in 69% of the 100 patients studied, procainamide was effective in 50% of the 75 patients studied, and lidocaine prevented VT induction in 30% of 53 patients. Following PES and serial drug testing, 46 patients were started on lorcainide, nine patients on procainamide, and 45 patients were started on other antiarrhythmic drug regimens. Seventy percent of the patients have remained on lorcainide therapy, while 47% have continued on other drug therapies started over a 20.5 +/- 3.2-month mean follow-up period. Despite sleep-wake disturbances and a need for sedation at night, lorcainide therapy was tolerated well in this population and remained an effective antiarrhythmic with prolonged administration.
Volume
109
Issue
1
First Page
33
Last Page
40
ISSN
0002-8703
Published In/Presented At
Somberg, J., Butler, B., Flowers, D., Keefe, D., Torres, V., & Miura, D. (1985). Long-term lorcainide therapy in patients with ventricular tachycardia. American heart journal, 109(1), 33–40. https://doi.org/10.1016/0002-8703(85)90412-0
Disciplines
Medicine and Health Sciences
PubMedID
3966330
Department(s)
Department of Medicine
Document Type
Article